Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Popular weight-loss drugs Ozempic and Wegovy may slow biological aging By calming inflammation and reducing excess fat, semaglutide may postpone several molecular signs of aging, pointing to the potential of GLP1 receptor agonists to help prevent agerelated diseases Date: July 14, 2026 Source: University of California - San Diego Summary: Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging
The data depth on weekly subcutaneous semaglutide spans more patients over more years than any oral formulation
For additional perspective, heres a list of more studies that show the same: A potential link between liraglutide and thyroid cancer (along with pancreatic and gallbladder problems as well) (3) Study highlighting that liraglutide should not be used in people with a family history of medullary thyroid cancer (4) A study showing there is no increase in the risk of thyroid cancer (for additional perspective) (5) A meta-analysis showing that there is not enough evidence to suggest there is a link between thyroid cancer and GLP-1 agonists (6) Its worth pointing out that while there is still debate on this topic, the larger and bigger studies on this issue seem to support a connection between the two
Glucagon-like peptide-1 receptor agonist attenuates autophagy to ameliorate pulmonary arterial hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3beta pathways
